Most neuroendocrine tumors are diagnosed by biomarker testing. Imaging and endoscopic modalities can localize the original site of the tumors and their metastasis. A wide range of diagnostic tools are available at the Baylor St. Luke’s Medical Center Neuroendocrine Tumor Program to support our effort to make an accurate diagnosis.
- Computed Tomography (CT-scan): Triple phase helical CT-scan images are recommended for localization and staging of neuroendocrine tumors. Neuroendocrine tumors are generally vascular tumors that enhance intensely with intravenous contrast injection during the arterial phase imaging with washout during the delayed portal venous phase. This is also available at our Kirby Glen location.
- Magnetic Resonance Imaging (MRI): Is preferred over CT for patients with a history of allergy to iodine contrast. In addition to a closed MRI, St. Luke's is taking imaging to new heights, offering Houston's first site for a new panoramic, wide-open, high-field MRI. This is also available at our Kirby Glen location. We provide:
- Exceptional image quality
- More space, more comfort
- Unlimited joint positioning
- Imaging for any patient, large or claustrophobicescan??): Provides a useful tool to detect metastatic disease in unsuspected sites. This technique utilizes a radio-labeled contrast agent (Indium 111-labeled somatostatin analog) administered intravenously prior to scintigraphy with a special large field gamma camera. The overall sensitivity is about 80 percent to 90 percent.
- 131- IodineMetaiodobenzylguanidine (MIBG) Scintigraphy: Useful for identifying pheochromocytoma.
- Positron Emission Tomography (PET-scan) using 18-flurodeoxyglucose (FDG) Imaging: Useful in detecting high grade neuroendocrine tumors as a result of their high proliferative activity.